home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610780.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
3KB
|
41 lines
Document 0780
DOCN M9610780
TI Hospital costs of treating haemophilic patients infected with HIV.
DT 9601
AU Kennelly JM; Tolley KH; Ghani AC; Sabin CA; Maynard AK; Lee CA;
Haemophilia Centre, Royal Free Hospital, London, UK.
SO AIDS. 1995 Jul;9(7):787-93. Unique Identifier : AIDSLINE MED/96035243
AB OBJECTIVE: To calculate the costs of treating HIV-infected haemophilic
patients. DESIGN: Two-year retrospective study of hospital-based
resource use and costs, from April 1991 to March 1993. SETTING:
Haemophilia Centre and Haemostasis Unit, Royal Free Hospital and School
of Medicine, London, UK. PATIENTS: Sixty patients infected with HIV
between October 1979 and July 1985. RESULTS: During the 2-year period a
total of 1668 hospital visits were made by patients. The mean number of
episodes per patient-year (PY) was 0.6 inpatient admissions, 11.5
outpatient visits and 1.8 day cases. The mean cost per PY was 32,528
pounds, with the majority of this spent on clotting factor concentrate
products and haemophilia inpatient admissions (81%). A mean cost for
HIV-related treatment of 6050 pounds was estimated. The additional cost
incurred in switching this group of haemophilic patients from
intermediate-purity factor concentrate to high-purity products was 8614
pounds per PY. When clotting factor concentrate and expenditure on
haemophilia-related inpatient admissions were excluded, the mean cost of
treating HIV infection per PY was 6065 pounds, varying with CD4+ count
(< or = 50 x 10(6)/l, 13,093 pounds; 51-200 x 10(6)/l, 6521 pounds;
201-500 x 10(6)/l, 2848 pounds; > 501 x 10(6)/l, 1497 pounds).
CONCLUSIONS: CD4+ count may be used as a marker of costs of HIV
infection. The HIV-related cost estimates can be used for the planning
of current and future hospital-based care in the National Health Service
in the United Kingdom. The switch from intermediate-purity factor
concentrate to high-purity products has increased the mean HIV-related
cost per PY of treating haemophilic patients infected with HIV.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS/DRUG THERAPY/
*ECONOMICS Adult Aged CD4 Lymphocyte Count
Hemophilia/COMPLICATIONS/*ECONOMICS/THERAPY *Hospital Costs Human
London Male Middle Age Support, Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).